ReviewInternational journal of molecular sciences2025
Towards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Domain-Adaptive Transfer Learning for HPV Lesion Classification in Whole Slide Images: A Patient-Level Pipeline Across the Cytology-Histology Continuum.Bioengineering (Basel, Switzerland) · 2026Article
- Next-Generation Artificial Intelligence Strategies for Mechanistic Cancer Target Discovery and Drug Development: A State-of-the-Art Review.International journal of molecular sciences · 2026Review
- Further Promise and Potential for Precision Medicine in Oncology.Journal of medical Internet research · 2026Article
- Review
- A Tumor-Agnostic, Topology-Informed Scoring Framework for Drug Repurposing: Application to CDK4/6 Inhibitor Resistance in HRBiomedicines · 2026Article
- Article
- Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026Review
- From Semantic Modeling to Precision Radiotherapy: An AI Framework Linking Radiobiology, Oncology, and Public Health Integration.Biomedicines · 2025Review
- From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology.Targeted oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in precision oncology have led to significant breakthroughs through the targeting of defined oncogenic drivers. However, the clinical efficacy of single-target therapies is increasingly constrained by the intrinsic complexity and adaptability of cancer. Solid tumors frequently arise from multifactorial oncogenic processes and adapt via diverse resistance mechanisms, ultimately limiting the durability of monotherapies. This review advocates for a paradigm shift toward multi-targeted, AI-enhanced strategies that harness high-throughput multi-omic data to inform the rational design of combination therapies. By leveraging artificial intelligence for drug discovery and repurposing, response prediction, and clinical trial optimization, the field of oncology is poised to transcend reductionist approaches and more fully address the biological intricacy of cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.